Treatment
Decitabine and Cedazuridine clinical trials
We’re tracking 14 recruiting studies that include Decitabine and Cedazuridine, each written for real people, not researchers, below.
Recruiting studies
- NCT07012044RecruitingPhase 1
Cedazuridine and decitabine after stem cell transplant for childhood leukemia
This trial tests if adding two chemotherapy drugs (cedazuridine and decitabine) along with a growth factor (filgrastim) can help prevent leukemia from coming back after a stem cell transplant. It is for children and young adults with high-risk acute myeloid leukemia who are in remission after transplant.
Birmingham, AlabamaAges Up to 21 years - NCT06577441RecruitingPhase 2
Adding enasidenib to usual care for higher-risk MDS with IDH2 mutation
This trial tests whether adding enasidenib (a targeted pill) to the standard chemotherapy (cedazuridine-decitabine) works better than the chemotherapy alone for people with higher-risk myelodysplastic syndrome (MDS) whose cells have a specific change in the IDH2 gene.
Berkeley, CaliforniaAges 18 years+ - NCT07148947RecruitingPhase 2
Pacritinib with standard care before stem cell transplant for MPN
This trial tests adding pacritinib to standard hypomethylating agents (azacitidine or decitabine) before a stem cell transplant for people with myeloproliferative neoplasms (MPN) that have progressed to a more advanced phase.
Seattle, WashingtonAges 18 years+ - NCT05010772RecruitingPhase 1
Maintenance treatment study for AML in remission
This Phase 1 trial tests whether continuing decitabine alone or with other targeted drugs can help prevent AML from coming back after you reach remission. It’s designed to study safety and how well these maintenance options work for people who are not immediately able to get a stem cell transplant.
Houston, TexasAges 18 years+ - NCT07437950RecruitingPhase 2
Comparing treatment lengths for venetoclax in older adults with newly diagnosed acute myeloid leukemia
This study tests whether a shorter or longer course of the drug venetoclax works better for older adults with a type of blood cancer called acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. The goal is to find the best treatment duration to control the cancer while reducing side effects.
Bloomington, IllinoisAges 60 years+ - NCT06672146RecruitingPhase 2
New treatments for AML with an IDH2 mutation
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
Tucson, ArizonaAges 18 years+ - NCT05564390RecruitingPhase 2
MyeloMATCH screening to match you to AML or MDS treatment
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Birmingham, AlabamaAges 18 years+ - NCT06661915RecruitingPhase 2
Combination treatment for advanced myeloproliferative neoplasms
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
Irvine, CaliforniaAges 18 years+ - NCT04774393RecruitingPhase 1/Phase 2
Study for AML after it returns or resists treatment
This Phase 1/2 trial tests a combination of medicines (decitabine/cedazuridine, venetoclax, and ivosidenib or enasidenib) in people with acute myeloid leukemia (AML) that has come back or hasn’t responded. It may help control the leukemia by targeting cancer cells and specific genetic changes in the leukemia.
Houston, TexasAges 18 years+ - NCT04953897RecruitingPhase 1
Oral decitabine for cancer patients with kidney problems
This Phase 1 trial studies how an oral combination cancer medicine behaves in the body (dose handling and safety) in people with kidney impairment. It may help doctors learn the safest way to use this treatment when kidney function is reduced.
Houston, TexasAges 18 years+ - NCT04953910RecruitingPhase 1
Oral decitabine for cancers with liver problems
This Phase 1 trial studies how a pill form of decitabine/cedazuridine behaves in the body and how safe it is for people whose livers don’t work normally. It may help doctors better understand dosing and safety in patients with hepatic impairment.
Houston, TexasAges 18 years+ - NCT05010122RecruitingPhase 1/Phase 2
Testing venetoclax and gilteritinib with ASTX727 for FLT3 leukemia
This Phase 1/2 trial tests a combination of medicines (ASTX727, venetoclax, and gilteritinib) for adults with FLT3-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to see how well the treatment works and how safe it is for people whose disease has come back, is not responding, or (for some) is newly diagnosed.
Houston, TexasAges 18 years+ - NCT05272384RecruitingPhase 1
Testing nivolumab plus ASTX727 for hard-to-treat lymphoma
This Phase 1 study tests whether adding ASTX727 to nivolumab can shrink relapsed or refractory B-cell lymphomas that have come back or did not respond to treatment. It also aims to find a safe dosing plan and see early signs of benefit in certain lymphoma types.
Birmingham, AlabamaAges 18 years+ - NCT06484062RecruitingPhase 1
Testing cirtuvivint alone and with ASTX727 for leukemia and MDS
This trial tests a new drug called cirtuvivint, given alone or with another drug (ASTX727), for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that has come back or not responded to treatment, and for people with high-risk MDS who have not been treated before. The goal is to see if these combinations work better than current options.
New Haven, ConnecticutAges 18 years+
What Decitabine and Cedazuridine is being studied for
Conditions with recruiting Decitabine and Cedazuridine studies.
- Acute Myeloid Leukemia
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Acute Myeloid Leukemia Post Cytotoxic Therapy
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Hodgkin Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
Common questions
- Are there clinical trials studying Decitabine and Cedazuridine?
- Yes. Clin2 currently lists 14 recruiting studies that include Decitabine and Cedazuridine, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Decitabine and Cedazuridine trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Decitabine and Cedazuridine an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Decitabine and Cedazuridine or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.